Nanoparticle technology for treatment of Parkinson’s disease: The role of surface phenomena in reaching the brain

Renal clearance of quantum dots

Soo Choi, H., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Itty Ipe, B., Bawendi, M. G., & Frangioni, J. V. (2007) · Nature Biotechnology · doi:10.1038/nbt1340 · Cited by 4,476

Epidemiology of Parkinson's disease

de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110

Solid lipid nanoparticles (SLN) for controlled drug delivery – a review of the state of the art

Müller, R. (2000) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/s0939-6411(00)00087-4 · Cited by 3,836

Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles

OWENSIII, D., & PEPPAS, N. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.10.010 · Cited by 3,637

Poly(ethylene glycol) in Drug Delivery: Pros and Cons as Well as Potential Alternatives

Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010) · Angewandte Chemie International Edition · doi:10.1002/anie.200902672 · Cited by 3,533

Understanding the nanoparticle–protein corona using methods to quantify exchange rates and affinities of proteins for nanoparticles

Cedervall, T., Lynch, I., Lindman, S., Berggård, T., Thulin, E., Nilsson, H., Dawson, K. A., & Linse, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608582104 · Cited by 3,281

Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts

Lundqvist, M., Stigler, J., Elia, G., Lynch, I., Cedervall, T., & Dawson, K. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805135105 · Cited by 3,037

Nanoparticle PEGylation for Imaging and Therapy

Jokerst, J. V., Lobovkina, T., Zare, R. N., & Gambhir, S. S. (2011) · Nanomedicine · doi:10.2217/nnm.11.19 · Cited by 2,113

Physical−Chemical Aspects of Protein Corona: Relevance to in Vitro and in Vivo Biological Impacts of Nanoparticles

Monopoli, M. P., Walczyk, D., Campbell, A., Elia, G., Lynch, I., Baldelli Bombelli, F., & Dawson, K. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja107583h · Cited by 1,835

Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment

Chaudhuri, К. R., & Schapira, A. H. V. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70068-7 · Cited by 1,818

Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity

Eeden, S. K. V. D. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,805

Understanding and controlling the interaction of nanomaterials with proteins in a physiological environment

Walkey, C. D., & Chan, W. C. W. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15233e · Cited by 1,758

Encyclopedia of pharmaceutical technology

(2003) · Choice Reviews Online · doi:10.5860/choice.40-6157 · Cited by 1,744

‘Stealth’ corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption

Gref, R., Lück, M., Quellec, P., Marchand, M., Dellacherie, E., Harnisch, S., Blunk, T., & Müller, R. H. (2000) · Colloids and Surfaces B Biointerfaces · doi:10.1016/s0927-7765(99)00156-3 · Cited by 1,725

Freeze-drying of nanoparticles: Formulation, process and storage considerations

ABDELWAHED, W., DEGOBERT, G., STAINMESSE, S., & FESSI, H. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.017 · Cited by 1,611

Pharmacological Treatment of Parkinson Disease

Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,510

Interpretation of Protein Adsorption: Surface-Induced Conformational Changes

Roach, P., Farrar, D. F., & Perry, C. C. (2005) · Journal of the American Chemical Society · doi:10.1021/ja042898o · Cited by 1,487

Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles

Reis, C. P., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2005.12.003 · Cited by 1,355

Effect of covalent attachment of polyethylene glycol on immunogenicity and circulating life of bovine liver catalase.

Abuchowski, A., McCoy, J. R., Palczuk, N. C., Es, T. V., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,276

Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties

Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,228

Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation

KECK, C., & MULLER, R. (2006) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2005.05.009 · Cited by 1,061

Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution

Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., & McNeil, S. E. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800032f · Cited by 1,022

Nanoparticle-induced unfolding of fibrinogen promotes Mac-1 receptor activation and inflammation

Deng, Z. J., Liang, M., Monteiro, M. J., Tóth, I., & Minchin, R. F. (2010) · Nature Nanotechnology · doi:10.1038/nnano.2010.250 · Cited by 893

Approaches to transport therapeutic drugs across the blood–brain barrier to treat brain diseases

Gabathuler, R. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.028 · Cited by 829

Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability

Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742

Parameters influencing the stealthiness of colloidal drug delivery systems

Vonarbourg, A., Passirani, C., Saulnier, P., & Benoit, J.-P. (2006) · Biomaterials · doi:10.1016/j.biomaterials.2006.03.039 · Cited by 740

The accelerated blood clearance (ABC) phenomenon: Clinical challenge and approaches to manage

Abu Lila, A. S., Kiwada, H., & Ishida, T. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.07.026 · Cited by 721

Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN™) dispersions

Freitas, C., & Müller, R. H. (1998) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(98)00092-1 · Cited by 690

Immune activation in brain aging and neurodegeneration: too much or too little?

Lucin, K. M., & Wyss-Coray, T. (2009) · Neuron · doi:10.1016/j.neuron.2009.08.039 · Cited by 679

In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space

Thorne, R. G., & Nicholson, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509425103 · Cited by 641

Potential of solid lipid nanoparticles in brain targeting.

Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615

Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood–brain barrier (BBB)

Ulbrich, K., Hekmatara, T., Herbert, E., & Kreuter, J. (2009) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.021 · Cited by 591

Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes

Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., & Kiwada, H. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.01.005 · Cited by 558

Drug delivery to the central nervous system by polymeric nanoparticles: What do we know?

Kreuter, J. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.008 · Cited by 554

Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles)

Kreuter, J., Alyautdin, R. N., Kharkevich, D. A., & Aa, I. (1995) · Brain Research · doi:10.1016/0006-8993(95)00023-j · Cited by 538

Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes

Ishida, T., & Kiwada, H. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.11.005 · Cited by 496

Priorities in Parkinson's disease research

Meissner, W. G., Frasier, M. A., Gasser, T., Goetz, C. G., Lozano, A. M., Piccini, P. P., Obeso, J. A., Rascol, O., Schapira, A. H. V., Voon, V., et al. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3430 · Cited by 461

Curcumin Loaded-PLGA Nanoparticles Conjugated with Tet-1 Peptide for Potential Use in Alzheimer's Disease

Mathew, A., Fukuda, T., Nagaoka, Y., Hasumura, T., Morimoto, H., Yoshida, Y., Maekawa, T., Venugopal, K., & Kumar, D. S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032616 · Cited by 454

Drug delivery to the central nervous system: a review.

Misra, A. R., Ganesh, S. D., Shahiwala, A., & Shah, S. P. (2003) · PubMed · Cited by 435

Parkinson's Disease in a Chemist Working with 1-Methyl-4-Phenyl-L,2,5,6-Tetrahydropyridine

Langston, J. W., & Ballard, P. A. (1983) · New England Journal of Medicine · doi:10.1056/nejm198308043090511 · Cited by 406

A Coarse-Grained Model for Polyethylene Oxide and Polyethylene Glycol: Conformation and Hydrodynamics

Lee, H., de Vries, A. H., Marrink, ‪. J., & Pastor, R. W. (2009) · The Journal of Physical Chemistry B · doi:10.1021/jp9058966 · Cited by 405

Mitochondria-targeted antioxidants for treatment of Parkinson's disease: Preclinical and clinical outcomes

Jin, H., Kanthasamy, A., Ghosh, A., Anantharam, V., Kalyanaraman, B., & Kanthasamy, A. G. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.09.007 · Cited by 373

Drug delivery to the central nervous system: A review

Tamargo, R. J., & Brem, H. (1992) · Neurosurgery Quarterly · Cited by 369

Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: Effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes

Ishida, T., Harada, M., Wang, X., Ichihara, M., Irimura, K., & Kiwada, H. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.04.003 · Cited by 365

Receptor-Mediated Delivery of Magnetic Nanoparticles across the Blood–Brain Barrier

Qiao, R., Jia, Q., Hüwel, S., Xia, R., Liu, T., Gao, F., Galla, H., & Gao, M. (2012) · ACS Nano · doi:10.1021/nn300240p · Cited by 333

Assessment of PEG on polymeric particles surface, a key step in drug carrier translation

Rabanel, J., Hildgen, P., & Banquy, X. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.017 · Cited by 327

The hallmarks of P arkinson's disease

Antony, P. M. A., Diederich, N. J., Krüger, R., & Balling, R. (2013) · FEBS Journal · doi:10.1111/febs.12335 · Cited by 317

Neurotoxicant-induced animal models of Parkinson?s disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration

Uversky, V. N. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0937-z · Cited by 317

Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats

Fundaro', A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., & Gasco, M. R. (2000) · Pharmacological Research · doi:10.1006/phrs.2000.0695 · Cited by 317

Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: Pharmacodynamic, Pharmacokinetic and Scintigraphy study in mice model

Md, S., Khan, R. A., Mustafa, G., Chuttani, K., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.12.007 · Cited by 307

Antibodies against Polyethylene Glycol Produced in Animals by Immunization with Monomethoxy Polyethylene Glycol Modified Proteins

Richter, A. W., & Akerblom, E. B. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000233309 · Cited by 282

Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: Preparation, characterization and efficacy in Parkinson's disease

Hu, K., Shi, Y., Jiang, W., Han, J., Huang, S., & Jiang, X. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.062 · Cited by 272

Delivery of gold nanoparticles to the brain by conjugation with a peptide that recognizes the transferrin receptor

Prades, R., Guerrero, S., Araya, E., Molina-Pelayo, C., Salas‐Huenuleo, E., Zurita, E., Selva, J., Egea, G., López‐Iglesias, C., Teixidò, M., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.063 · Cited by 269

Uptake Mechanism of ApoE-Modified Nanoparticles on Brain Capillary Endothelial Cells as a Blood-Brain Barrier Model

Wagner, S., Zensi, A., Wien, S., Tschickardt, S., Maier, W., Vogel, T., Worek, F., Pietrzik, C. U., Kreuter, J., & von Briesen, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032568 · Cited by 265

Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density

Vila, A., Gill, H., McCallion, O. N. M., & Alonso, M. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.04.026 · Cited by 249

Uptake and transport of high‐density lipoprotein (HDL) and HDL‐associated α‐tocopherol by an in vitro blood–brain barrier model

Balázs, Z., Panzenboeck, U., Hammer, A., Sovic, A., Quehenberger, O., Malle, E., & Sattler, W. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02373.x · Cited by 245

Odorranalectin-conjugated nanoparticles: Preparation, brain delivery and pharmacodynamic study on Parkinson's disease following intranasal administration

Wen, Z., Yan, Z., Hu, K., Pang, Z., Cheng, X., Guo, L., Zhang, Q., Jiang, X., Fang, L., & Lai, R. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.022 · Cited by 241

Characterization and evaluation of chitosan nanoparticles for dopamine brain delivery

Trapani, A., De Giglio, E., Cafagna, D., Denora, N., Agrimi, G., Cassano, T., Gaetani, S., Cuomo, V., & Trapani, G. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.07.036 · Cited by 238

Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123

Tosi, G., Costantino, L., Rivasi, F., Ruozi, B., Leo, E., Vergoni, A. V., Tacchi, R., Bertolini, A., Vandelli, M. A., & Forni, F. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.05.022 · Cited by 236

Rivastigmine-loaded PLGA and PBCA nanoparticles: Preparation, optimization, characterization, in vitro and pharmacodynamic studies

Joshi, S. A., Chavhan, S. S., & Sawant, K. K. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.07.007 · Cited by 235

Uptake of ANG1005, A Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer

Thomas, F. C., Taskar, K. S., Rudraraju, V., Goda, S., Thorsheim, H. R., Gaasch, J. A., Mittapalli, R. K., Palmieri, D., Steeg, P. S., Lockman, P. R., et al. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9964-5 · Cited by 227

Solid lipid nanoparticles as vehicles of drugs to the brain: Current state of the art

Gastaldi, L., Battaglia, L., Peira, E., Chirio, D., Muntoni, E., Solazzi, I., Gallarate, M., & Dosio, F. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.05.004 · Cited by 227

The genetics of Parkinson's syndromes: a critical review

Hardy, J., Lewis, P. A., Révész, T., Lees, A. J., & Paisán‐Ruiz, C. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2009.03.008 · Cited by 216

Nanoencapsulation II. Biomedical applications and current status of peptide and protein nanoparticulate delivery systems

Reis, C. P., Neufeld, R. J., Ribeiro, A. J., & Veiga, F. (2006) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2006.04.009 · Cited by 214

Peptide-derivatized biodegradable nanoparticles able to cross the blood–brain barrier

Costantino, L., Gandolfi, F., Tosi, G., Rivasi, F., Vandelli, M. A., & Forni, F. (2005) · Journal of Controlled Release · doi:10.1016/j.jconrel.2005.07.013 · Cited by 213

Amoxicillin-loaded polyethylcyanoacrylate nanoparticles: Influence of PEG coating on the particle size, drug release rate and phagocytic uptake

Fontana, G., Licciardi, M., Mansueto, S., Schillaci, D., & Giammona, G. (2001) · Biomaterials · doi:10.1016/s0142-9612(01)00030-8 · Cited by 192

Microbial Degradation of Poly(amino acid)s

Obst, M., & Steinbüchel, A. (2004) · Biomacromolecules · doi:10.1021/bm049949u · Cited by 191

A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood–Brain Barrier and Provides Neuroprotection

Karataş, H., Aktaş, Y., Özdemir, Y., Bodur, E., Yemişçi, M., Caban-Toktas, S., Vural, A., Pınarbaşlı, O., Çapan, Y., Fernández-Megía, E., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.4246-09.2009 · Cited by 191

Meta-analysis of Observational Studies

Greenwood, D. C. (2012) · Springer eBooks · doi:10.1007/978-94-007-3024-3_10 · Cited by 180

ABCA1 and Scavenger Receptor Class B, Type I, Are Modulators of Reverse Sterol Transport at an in Vitro Blood-Brain Barrier Constituted of Porcine Brain Capillary Endothelial Cells

Panzenboeck, U., Balazs, Z., Sovic, A., Hrzenjak, A., Levak-Frank, S., Wintersperger, A., Malle, E., & Sattler, W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207601200 · Cited by 169

Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery

Sharma, S., Lohan, S., & Murthy, R. S. R. (2013) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2013.789051 · Cited by 163

Freezing of Gait in Parkinson’s Disease: Where Are We Now?

Heremans, E., Nieuwboer, A., & Vercruysse, S. (2013) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-013-0350-7 · Cited by 159

Oral bioavailability, therapeutic efficacy and reactive oxygen species scavenging properties of coenzyme Q10-loaded polymeric nanoparticles

Swarnakar, N. K., Jain, A., Singh, R. P., Godugu, C., Das, M., & Jain, S. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.05.079 · Cited by 155

Particle size-dependent triggering of accelerated blood clearance phenomenon

Koide, H., Asai, T., Hatanaka, K., Urakami, T., Ishii, T., Kenjo, E., Nishihara, M., Yokoyama, M., Ishida, T., Kiwada, H., et al. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.06.004 · Cited by 148

Therapeutic prospects for Parkinson disease

Olanow, C. W., & Schapira, A. H. V. (2013) · Annals of Neurology · doi:10.1002/ana.24011 · Cited by 145

Oral Apomorphine Delivery from Solid Lipid Nanoparticles with Different Monostearate Emulsifiers: Pharmacokinetic and Behavioral Evaluations

Tsai, M.-J., Huang, Y.-B., Wu, P.-C., Fu, Y.-S., Kao, Y.-R., Fang, J.-Y., & Tsai, Y.-H. (2011) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22285 · Cited by 137

PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation

Muthu, M. S., Rawat, M. K., Mishra, A., & Singh, S. K. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2008.12.003 · Cited by 136

Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs

Suzuki, T., Ichihara, M., Hyodo, K., Yamamoto, E., Ishida, T., Kiwada, H., Ishihara, H., & Kikuchi, H. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.07.049 · Cited by 127

Theranostic liposomes loaded with quantum dots and apomorphine for brain targeting and bioimaging

Fang, J., Wen, C.-J., Zhang, Z., Al-Suwayeh, & Yen, T. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s29369 · Cited by 126

Surfactants, not size or zeta-potential influence blood–brain barrier passage of polymeric nanoparticles

Voigt, N., Henrich‐Noack, P., Kockentiedt, S., Hintz, W., Tomas, J., & Sabel, B. A. (2014) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2014.02.013 · Cited by 124

Toxicity of Polyalkylcyanoacrylate Nanoparticles I: Free Nanoparticles

Kante, B., Couvreur, P., Dubois-Krack, G., de Meester, C., Guiot, P., Roland, M., Mercier, M., & Speiseru, P. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710716 · Cited by 121

Nanoparticulate lipid dispersions for bromocriptine delivery: Characterization and in vivo study

Esposito, E., Mariani, P., Ravani, L., Contado, C., Volta, M., Bido, S., Drechsler, M., Mazzoni, S., Menegatti, E., Morari, M., et al. (2011) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2011.10.015 · Cited by 119

Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials

Kalia, L., Brotchie, J., & Fox, S. H. (2013) · Movement Disorders · doi:10.1002/mds.25273 · Cited by 116

Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety

Nagpal, K., Singh, S. K., & Mishra, D. N. (2013) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2013.04.024 · Cited by 116

Non-dopaminergic treatments in development for Parkinson's disease

Fox, S. H., Brotchie, J. M., & Lang, A. E. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70214-x · Cited by 115

Epidemiology of Parkinson's disease

Liu, S., & Chan, P. (2016) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.3969/cjcnn.v16i2.1351 · Cited by 115

Neurotrophic and neuroprotective efficacy of intranasal GDNF in a rat model of Parkinson’s disease

Migliore, M. M., Ortiz, R., Dye, S., Campbell, R. B., Amiji, M. M., & Waszczak, B. L. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.05.019 · Cited by 107

Peptide-conjugated polyamidoamine dendrimer as a nanoscale tumor-targeted T1 magnetic resonance imaging contrast agent

Han, L., Li, J., Huang, S., Huang, R., Liu, S., Hu, X., Yi, P., Shan, D., Wang, X., Lei, H. C., et al. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.01.005 · Cited by 107

Emerging therapies for Parkinson's disease: From bench to bedside

Tarazi, F. I., Sahli, Z. T., Wolny, M., & Mousa, S. A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.05.010 · Cited by 106

Motor and nonmotor complications in Parkinson’s disease: an argument for continuous drug delivery?

Chaudhuri, К. R., Rizos, A., & Sethi, K. D. (2013) · Journal of Neural Transmission · doi:10.1007/s00702-013-0981-5 · Cited by 104

A Unique Carrier for Delivery of Therapeutic Compounds beyond the Blood-Brain Barrier

Karkan, D., Pfeifer, C. G., Vitalis, T. Z., Arthur, G., Ujiie, M., Chen, Q., Tsai, S., Koliatis, G., Gabathuler, R., & Jefferies, W. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002469 · Cited by 104

Parkinson's Disease – the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis

Jenner, P. G., Morris, H. R., Robbins, T. W., Goedert, M., Hardy, J., Ben‐Shlomo, Y., Bolam, J. P., Burn, D. J., Hindle, J. V., Brooks, D. J., et al. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130175 · Cited by 103

Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents?

Costantino, L., & Boraschi, D. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.10.028 · Cited by 103

In VitroandIn VivoStudy of Solid Lipid Nanoparticles Loaded with Superparamagnetic Iron Oxide

Peira, E., Marzola, P., Podio, V., Aime, S., Sbarbati, A., & Gasco, M. R. (2003) · Journal of drug targeting · doi:10.1080/1061186031000086108 · Cited by 102

Neuroprotection in a 6‐hydroxydopamine‐lesioned Parkinson model using lactoferrin‐modified nanoparticles

Huang, R., Han, L., Li, J., Ren, F., Ke, W., Jiang, C., & Pei, Y. (2009) · The Journal of Gene Medicine · doi:10.1002/jgm.1361 · Cited by 100

Dynamics of Nanoparticle-Protein Corona Complex Formation: Analytical Results from Population Balance Equations

Sahneh, F. D., Scoglio, C., & Riviere, J. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0064690 · Cited by 99

Purification of nanoparticle suspensions by a concentration/diafiltration process

Limayem, I., Charcosset, C., & Fessi, H. (2003) · Separation and Purification Technology · doi:10.1016/j.seppur.2003.10.002 · Cited by 99

Increasing the Effciency of Parkinson’s Disease Treatment Using a poly(lactic-co-glycolic acid) (PLGA) Based L-DOPA Delivery System

Gambaryan, P. Y., Кондрашева, И. Г., Severin, E. S., Guseva, A. A., & Kamensky, A. A. (2014) · Experimental Neurobiology · doi:10.5607/en.2014.23.3.246 · Cited by 97

Novel surface modified polymer–lipid hybrid nanoparticles as intranasal carriers for ropinirole hydrochloride: in vitro, ex vivo and in vivo pharmacodynamic evaluation

Pardeshi, C. V., Belgamwar, V. S., Tekade, A. R., & Surana, S. J. (2013) · Journal of Materials Science Materials in Medicine · doi:10.1007/s10856-013-4965-7 · Cited by 95

Drug development in Parkinson's disease: From emerging molecules to innovative drug delivery systems

Garbayo, E., Ansorena, E., & Blanco‐Prieto, M. J. (2013) · Maturitas · doi:10.1016/j.maturitas.2013.05.019 · Cited by 83

Design, biometric simulation and optimization of a nano-enabled scaffold device for enhanced delivery of dopamine to the brain

Pillay, S., Pillay, V., Choonara, Y. E., Naidoo, D., Khan, R. A., du Toit, L. C., Ndesendo, V. M. K., Modi, G., Danckwerts, M. P., & Iyuke, S. E. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.08.021 · Cited by 80

Scaling up feasibility of the production of solid lipid nanoparticles (SLN).

Gohla, S., & Dingler, A. (2001) · PubMed · Cited by 78

β-Hydroxybutyric acid grafted solid lipid nanoparticles: A novel strategy to improve drug delivery to brain

Venishetty, V. K., Samala, R., Komuravelli, R., Kuncha, M., Sistla, R., & Diwan, P. V. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.08.004 · Cited by 73

Nicotine-encapsulated poly(lactic-co-glycolic) acid nanoparticles improve neuroprotective efficacy against MPTP-induced parkinsonism

Tiwari, M. N., Agarwal, S., Bhatnagar, P., Singhal, N. K., Tiwari, S. K., Kumar, P., Chauhan, L. K. S., Patel, D. K., Chaturvedi, R. K., Singh, M. P., et al. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.07.042 · Cited by 70

Development and Evaluation of Perfluorocarbon Nanobubbles for Apomorphine Delivery

Hwang, T., Lin, Y., Chi, C.-H., Huang, T., & Fang, J. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21687 · Cited by 69

Production and characterization of novel chitosan nanoparticles for controlled release of rHu-Erythropoietin

Bulmer, C., Margaritis, A., & Xenocostas, A. (2012) · Biochemical Engineering Journal · doi:10.1016/j.bej.2012.07.007 · Cited by 68

Potential applications of nanotechnologies to Parkinson's disease therapy

Linazasoro, G. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2007.11.012 · Cited by 65

Involvement of dopamine loss in extrastriatal basal ganglia nuclei in the pathophysiology of Parkinson’s disease

Benazzouz, A., Mamad, O., Abedi, P., Bouali‐Benazzouz, R., & Chetrit, J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00087 · Cited by 64

Studies on Biodegradable Polymeric Nanoparticles of Risperidone: In Vitro and In Vivo Evaluation

Muthu, M. S., & Singh, S. K. (2008) · Nanomedicine · doi:10.2217/17435889.3.3.305 · Cited by 59

Enfermedad de Parkinson avanzada. Características clínicas y tratamiento (parte I)

Kulisevsky, J., Luquín, M. R., Arbelo, J. M., Burguera, J. A., Carrillo, F., Castro, A., Chacón, J., Ruiz, P., Lezcano, E., Mir, P., et al. (2013) · Neurología · doi:10.1016/j.nrl.2013.05.001 · Cited by 59

Physicochemical characterization andin vivobioluminescence imaging of nanostructured lipid carriers for targeting the brain: apomorphine as a model drug

Hsu, S.-H., Wen, C.-J., Al‐Suwayeh, S. A., Chang, H., Yen, T., & Fang, J. (2010) · Nanotechnology · doi:10.1088/0957-4484/21/40/405101 · Cited by 58

Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats

Yuan, W., Yang, X., Zheng, R., Cai, Y., Liao, M., & Liu, Z. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s30463 · Cited by 56

Advanced Parkinson's disease: Clinical characteristics and treatment (part 1)

Kulisevsky, J., Luquín, M. R., Arbelo, J. M., Burguera, J. A., Carrillo, F., Castro, A., Chacón, J., Ruiz, P., Lezcano, E., Mir, P., et al. (2013) · Neurología (English Edition) · doi:10.1016/j.nrleng.2013.05.002 · Cited by 56

NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease

Martínez‐Fong, D., Bannon, M. J., Trudeau, L., González-Barrios, J. A., Arango-Rodríguez, M. L., Hernández‐Chan, N. G., Reyes-Corona, D., Armendáriz‐Borunda, J., & Navarro-Quiroga, I. (2012) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2012.02.009 · Cited by 56

Genetics and iron in the systems biology of Parkinson’s disease and some related disorders

Funke, C., Schneider, S. A., Berg, D., & Kell, D. B. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.11.015 · Cited by 54

Sensing surface PEGylation with microcantilevers

Backmann, N., Kappeler, N., Braun, T., Huber, F., Lang, H. P., Gerber, C., & Lim, R. Y. H. (2010) · Beilstein Journal of Nanotechnology · doi:10.3762/bjnano.1.2 · Cited by 49

Influence of Surface-Modifying Surfactants on the Pharmacokinetic Behavior of 14C-Poly (Methylmethacrylate) Nanoparticles in Experimental Tumor Models

Lode, J., Fichtner, I., Kreuter, J., Berndt, A., Diederichs, J. E., & Reszka, R. C. (2001) · Pharmaceutical Research · doi:10.1023/a:1013094801351 · Cited by 47

Enfermedad de Parkinson avanzada. Características clínicas y tratamiento. Parte II

Kulisevsky, J., Luquín, M. R., Arbelo, J. M., Burguera, J. A., Carrillo, F., Castro, A., Chacón, J., Ruiz, P., Lezcano, E., Mir, P., et al. (2013) · Neurología · doi:10.1016/j.nrl.2013.05.002 · Cited by 43

Biopharmaceutical characterization of nanocrystalline solid dispersion of coenzyme Q10 prepared with cold wet-milling system

Onoue, S., Terasawa, N., Nakamura, T., Yuminoki, K., Hashimoto, N., & Yamada, S. (2013) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2013.12.013 · Cited by 43

Nanoparticle Formulation Improves the Anticonvulsant Effect of Clonazepam on the Pentylenetetrazole-Induced Seizures: Behavior and Electroencephalogram

Leyva‐Gómez, G., González-Trujano, M. E., López-Ruiz, E., Couraud, P., Wekslerg, B., Romero, I. A., Miller, F., Delié, F., Allémann, É., & Quintanar‐Guerrero, D. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24044 · Cited by 41

Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases

Gabathuler, R. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709788680652 · Cited by 41

Lipid nanoparticles for brain targeting II. Technological characterization

Blasi, P., Schoubben, A., Romano, G. V., Giovagnoli, S., Michele, A. D., & Ricci, M. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.04.021 · Cited by 40

Cabergoline use and risk of fibrosis and insufficiency of cardiac valves

Vecchis, R. D., Esposito, C., & Ariano, C. (2013) · Herz · doi:10.1007/s00059-013-3816-0 · Cited by 39

Formulation and Characterization of Nanostructured Lipid Carrier of Ubiquinone (Coenzyme Q10)

Nanjwade, B. K., Kadam, V. T., & Manvi, F. V. (2013) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2013.1560 · Cited by 38

Continuous dopaminergic stimulation and novel formulations of dopamine agonists

Stocchi, F. (2011) · Journal of Neurology · doi:10.1007/s00415-011-6024-y · Cited by 30

Combined strategies of apomorphine diester prodrugs and nanostructured lipid carriers for efficient brain targeting

Liu, K., Wen, C.-J., Yen, T., Sung, K. C., Ku, M.-C., Wang, J., & Fang, J. (2012) · Nanotechnology · doi:10.1088/0957-4484/23/9/095103 · Cited by 28

Effects of Levodopa loaded chitosan nanoparticles on cell viability and caspase-3 expression in PC12 neural like cells

Sadigh‐Eteghad, S., Talebi, M., Farhoudi, M., Mahmoudi, J., & Reyhani, B. (2013) · Neurosciences · doi:10.17712/1658-3183.2032 · Cited by 27

Fabrication, Modeling and Characterization of Multi-Crosslinked Methacrylate Copolymeric Nanoparticles for Oral Drug Delivery

Ngwuluka, N. C., Pillay, V., Choonara, Y. E., Modi, G., Naidoo, D., du Toit, L. C., Kumar, P., Ndesendo, V. M. K., & Khan, R. A. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12096194 · Cited by 21

Quinine, a selective gap junction blocker, decreases REM sleep in rats

Franco‐Pérez, J., & Paz, C. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.09.003 · Cited by 21

Parkin gene therapy

Mochizuki, H. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70012-4 · Cited by 10

Levodopa en el tratamiento de la enfermedad de Parkinson: mitos y realidades

Luquín, M. R., Ruiz, P., Martı́, M. J., Sebastián, A. R., Vela, L., Grandas, F., Bravo-Utrera, M., Burguera, J. A., Chacón, J., Arillo, V. M. C., et al. (2012) · Revista de Neurología · doi:10.33588/rn.5511.2012398 · Cited by 9

Continuing efforts to obtain continuous delivery of levodopa

Obeso, J. A., & Olanow, W. C. (2011) · Movement Disorders · doi:10.1002/mds.23996 · Cited by 8

Efficacy and Safety of Nasal Administration of “Na-no-L-DOPA” Based on PLGA Nanoparticles

Кондрашева, И. Г., Антипова, Т. А., Barsegyan, G. G., Gambaryan, P. Y., Guseva, A. A., & Kamensky, A. A. (2012) · Engineering · doi:10.4236/eng.2012.410b007 · Cited by 8

Dementia – The real problem for patients with Parkinson's disease

Klingelhoefer, L., & Reichmann, H. (2014) · Basal Ganglia · doi:10.1016/j.baga.2014.03.003 · Cited by 6

Environmental pollutants as risk factors for neurodegenerative disorders: Alzheimer and Parkinson diseases

Chin-Chan, M., Navarro-Yepes, J., & Quintanilla‐Vega, B. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00124 · Cited by 746

Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses

Cortés, H., Hernández‐Parra, H., Bernal-Chávez, S. A., Prado-Audelo, M. L. D., Caballero-Florán, I. H., Borbolla‐Jiménez, F. V., González‐Torres, M., Magaña, J. J., & Leyva‐Gómez, G. (2021) · Materials · doi:10.3390/ma14123197 · Cited by 324

Stimuli-responsive In situ gelling system for nose-to-brain drug delivery

Agrawal, M., Saraf, S., Saraf, S., Dubey, S. K., Puri, A., Gupta, U. D., Kesharwani, P., Ravichandiran, V., Kumar, P., Naidu, V. G. M., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.044 · Cited by 304

Nano carriers for drug transport across the blood–brain barrier

Li, X.-M., Tsibouklis, J., Weng, T., Zhang, B.-N., Yin, G.-Q., Feng, G.-Z., Cui, Y.-D., Savina, I., Mikhalovska, L., Sandeman, S., et al. (2017) · Journal of drug targeting (Print) · doi:10.1080/1061186x.2016.1184272 · Cited by 217

The protein corona and its effects on nanoparticle-based drug delivery systems

Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265

Nanoparticles for drug delivery in Parkinson’s disease

Baskin, J., Jeon, J. E., & Lewis, S. J. G. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10291-x · Cited by 67

Recent Advancement in the Nanoparticles Mediated Therapeutics of Parkinson’s Disease

Chaturvedi, V. K., Singh, P., & singh, M. (2021) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9781681087726121010014 · Cited by 8

Theoretical and applied concepts of nanocarriers for the treatment of Parkinson's diseases

Bhosale, A., Paul, G., Mazahir, F., & Yadav, A. K. (2022) · OpenNano · doi:10.1016/j.onano.2022.100111 · Cited by 15

Nanomedicine to Overcome Current Parkinson’s Treatment Liabilities: A Systematic Review

Hawthorne, G. H., Bernuci, M. P., Bortolanza, M., Tumas, V., Issy, A. C., & Bel, E. A. D. (2016) · Neurotoxicity Research · doi:10.1007/s12640-016-9663-z · Cited by 24

Deciphering the Role of Nanoparticle-based Treatment for Parkinson’s Disease

Moni, M. M. R., Begum, M. M., Uddin, M. S., & Ashraf, G. M. (2021) · Current Drug Metabolism · doi:10.2174/1389200222666210202110129 · Cited by 15